busulfan has been researched along with Blood Diseases in 40 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A new intravenous (IV) dosing of busulfan (Bu) based on body weight, designed to improve AUC targeting without TDM and dose-adjustment, was prospectively evaluated." | 5.13 | Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. ( Doz, F; Espérou, H; Galambrun, C; Gentet, JC; Mechinaud, F; Michel, G; Neven, B; Nguyen, L; Puozzo, C; Valteau-Couanet, D; Vassal, G; Zouabi, H, 2008) |
| " To prevent from graft-versus-host disease (GVHD), cyclosporin A and short term methotrexate (MTX) were used." | 3.80 | [The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation]. ( Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B, 2014) |
| "The toxic effects of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) with autologous or syngeneic bone marrow rescue were evaluated in 19 patients (11 with acute myelocytic leukemia, one with acute lymphocytic leukemia, one with acute myelofibrosis, two with chronic myelocytic leukemia, one with Hodgkin's disease, and three with non-Hodgkin's lymphoma)." | 3.67 | Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. ( Braine, HG; Kaizer, H; Lu, C; Santos, GW; Saral, R; Tutschka, PJ, 1984) |
| " To decrease acute toxicities, we have prospectively evaluated a reduced intensity conditioning (RIC) regimen using targeted dosing of i." | 2.72 | Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. ( Baxter-Lowe, LA; Cowan, M; Desantes, K; Englert, L; Horn, B; McMillan, A; Quinn, M, 2006) |
| " This article reviews the current published literature on the dosing of pharmacologic agents used for HCT preparative regimens with specific focus on the obese patient population." | 2.50 | Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. ( Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J, 2014) |
| " We aimed this retrospective study for comparison of weight- and age-based dosing in terms of clinical outcomes such as time to engraftment, early complications, EFS, OS, and toxicity profiles in children receiving iv Bu." | 1.42 | Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. ( Avci, Z; Azik, F; Gürlek Gökçebay, D; Isik, P; Kara, A; Ozbek, N; Tavil, B; Tunc, B, 2015) |
| "Hyperbilirubinemia was graded according to a report by Hogan et al (Blood." | 1.33 | Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. ( Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K, 2006) |
| " Recent data revealed immunosuppressive characteristics and substantial haematopoietic stem cell toxicity after repeated dosing of mice." | 1.32 | Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). ( Baumgart, J; Becker, M; Fichtner, I, 2003) |
| "Data on 181 of 230 patients with aplastic anemia, leukemias, and lymphomas who had BMT before puberty (mean age, 9." | 1.30 | Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. ( Bakker, B; Cahn, JY; Cohen, A; Dopfer, R; Esperou, H; Gaiero, A; Kolb, HJ; Leiper, AD; Merlo, F; Rovelli, A; Socié, G; Uderzo, C; van Lint, MT, 1999) |
| " VP-16 concentrations were measured in all plasma samples by high-performance liquid chromatography (HPLC) and electrochemical detection, and the results were analyzed with a pharmacokinetic data analysis system." | 1.29 | Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. ( Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Stockschläder, M; Zander, A, 1994) |
| "Busulfan is a bifunctional alkylating agent that appears to be cytotoxic to slowly proliferating or non-proliferating stem cell compartments, although its specific molecular and cellular mechanisms are unknown." | 1.27 | Toxicological review of busulfan (Myleran). ( Bishop, JB; Wassom, JS, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (20.00) | 18.7374 |
| 1990's | 8 (20.00) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 12 (30.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esteves, I | 1 |
| Santos, FPS | 1 |
| Ribeiro, AAF | 1 |
| Seber, A | 1 |
| Sugawara, EK | 1 |
| Sobrinho, JJDN | 1 |
| Barros, JC | 1 |
| Oliveira, JSR | 1 |
| Fernandes, JF | 1 |
| Hamerschlak, N | 1 |
| Andersson, BS | 1 |
| de Lima, M | 1 |
| Kerbauy, FR | 1 |
| Araqi Houssaini, L | 1 |
| Hali, F | 1 |
| Quessar, A | 1 |
| Marnissi, F | 1 |
| Chiheb, S | 1 |
| Yu, SC | 1 |
| Huang, HH | 1 |
| Li, CC | 1 |
| Tang, JL | 1 |
| Lee, YH | 1 |
| Mao, TL | 1 |
| Kuo, KT | 1 |
| Lin, CT | 1 |
| Liu, JH | 1 |
| Ko, BS | 1 |
| Yao, M | 1 |
| Bubalo, J | 1 |
| Carpenter, PA | 1 |
| Majhail, N | 1 |
| Perales, MA | 1 |
| Marks, DI | 1 |
| Shaughnessy, P | 1 |
| Pidala, J | 1 |
| Leather, HL | 1 |
| Wingard, J | 1 |
| Savani, BN | 1 |
| Dirou, S | 1 |
| Malard, F | 1 |
| Chambellan, A | 1 |
| Chevallier, P | 1 |
| Germaud, P | 1 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| Moreau, P | 1 |
| Delasalle, B | 1 |
| Lemarchand, P | 1 |
| Mohty, M | 1 |
| Abedin, S | 1 |
| Peres, E | 1 |
| Levine, JE | 1 |
| Choi, S | 1 |
| Yanik, G | 1 |
| Couriel, DR | 1 |
| Tao, Y | 1 |
| Wu, B | 1 |
| Du, Q | 1 |
| Sun, C | 2 |
| Lin, X | 1 |
| Huang, Y | 1 |
| Tu, S | 1 |
| Song, C | 1 |
| Lu, Z | 1 |
| Chen, T | 1 |
| Yamamoto, H | 1 |
| Uchida, N | 1 |
| Matsuno, N | 1 |
| Kon, A | 1 |
| Nishida, A | 1 |
| Ota, H | 1 |
| Ikebe, T | 1 |
| Nakano, N | 1 |
| Ishiwata, K | 1 |
| Araoka, H | 1 |
| Takagi, S | 1 |
| Tsuji, M | 1 |
| Asano-Mori, Y | 1 |
| Yamamoto, G | 1 |
| Izutsu, K | 1 |
| Masuoka, K | 2 |
| Wake, A | 2 |
| Yoneyama, A | 1 |
| Makino, S | 1 |
| Taniguchi, S | 2 |
| Lawitschka, A | 1 |
| Faraci, M | 1 |
| Yaniv, I | 1 |
| Veys, P | 1 |
| Bader, P | 1 |
| Wachowiak, J | 1 |
| Socie, G | 2 |
| Aljurf, MD | 1 |
| Arat, M | 1 |
| Boelens, JJ | 1 |
| Duarte, R | 1 |
| Tichelli, A | 1 |
| Peters, C | 1 |
| Gürlek Gökçebay, D | 1 |
| Azik, F | 1 |
| Ozbek, N | 1 |
| Isik, P | 1 |
| Avci, Z | 1 |
| Tavil, B | 1 |
| Kara, A | 1 |
| Tunc, B | 1 |
| Yoshida, T | 1 |
| Kusumoto, S | 1 |
| Masuda, A | 1 |
| Totani, H | 1 |
| Narita, T | 1 |
| Masaki, A | 1 |
| Ito, A | 1 |
| Ri, M | 1 |
| Ishida, T | 1 |
| Komatsu, H | 1 |
| Iida, S | 1 |
| Shimony, O | 1 |
| Nagler, A | 1 |
| Gellman, YN | 1 |
| Refaeli, E | 1 |
| Rosenblum, N | 1 |
| Eshkar-Sebban, L | 1 |
| Yerushalmi, R | 1 |
| Shimoni, A | 1 |
| Lytton, SD | 1 |
| Stanevsky, A | 1 |
| Or, R | 1 |
| Naor, D | 1 |
| Crocchiolo, R | 1 |
| Esterni, B | 1 |
| Castagna, L | 1 |
| Fürst, S | 1 |
| El-Cheikh, J | 1 |
| Devillier, R | 1 |
| Granata, A | 1 |
| Oudin, C | 1 |
| Calmels, B | 1 |
| Chabannon, C | 1 |
| Bouabdallah, R | 1 |
| Vey, N | 1 |
| Blaise, D | 1 |
| Ahn, JS | 1 |
| Yang, DH | 1 |
| Jung, SH | 1 |
| Chae, YS | 1 |
| Sohn, SK | 1 |
| Yhim, HY | 1 |
| Kwak, JY | 1 |
| Lee, SR | 1 |
| Kim, YK | 1 |
| Kim, HJ | 1 |
| Lee, JJ | 1 |
| McCune, JS | 1 |
| Gooley, T | 1 |
| Gibbs, JP | 1 |
| Sanders, JE | 2 |
| Petersdorf, EW | 1 |
| Appelbaum, FR | 2 |
| Anasetti, C | 1 |
| Risler, L | 1 |
| Sultan, D | 1 |
| Slattery, JT | 1 |
| Wick, W | 1 |
| Hermisson, M | 1 |
| Kortmann, RD | 1 |
| Küker, WM | 1 |
| Duffner, F | 1 |
| Dichgans, J | 1 |
| Bamberg, M | 1 |
| Weller, M | 1 |
| Fichtner, I | 1 |
| Becker, M | 1 |
| Baumgart, J | 1 |
| Pföhler, C | 1 |
| Cree, IA | 1 |
| Ugurel, S | 1 |
| Kuwert, C | 1 |
| Haass, N | 1 |
| Neuber, K | 1 |
| Hengge, U | 1 |
| Corrie, PG | 1 |
| Zutt, M | 1 |
| Tilgen, W | 1 |
| Reinhold, U | 1 |
| Barker, CC | 1 |
| Butzner, JD | 1 |
| Anderson, RA | 1 |
| Brant, R | 1 |
| Sauve, RS | 1 |
| Horn, B | 1 |
| Baxter-Lowe, LA | 1 |
| Englert, L | 1 |
| McMillan, A | 1 |
| Quinn, M | 1 |
| Desantes, K | 1 |
| Cowan, M | 1 |
| Kusumi, E | 1 |
| Kami, M | 1 |
| Kanda, Y | 1 |
| Murashige, N | 1 |
| Seki, K | 1 |
| Fujiwara, M | 1 |
| Koyama, R | 1 |
| Komatsu, T | 1 |
| Hori, A | 1 |
| Tanaka, Y | 1 |
| Yuji, K | 1 |
| Matsumura, T | 1 |
| Miyakoshi, S | 1 |
| Vassal, G | 1 |
| Michel, G | 1 |
| Espérou, H | 2 |
| Gentet, JC | 1 |
| Valteau-Couanet, D | 1 |
| Doz, F | 1 |
| Mechinaud, F | 1 |
| Galambrun, C | 1 |
| Neven, B | 1 |
| Zouabi, H | 1 |
| Nguyen, L | 1 |
| Puozzo, C | 1 |
| Blau, IW | 1 |
| Schmidt-Hieber, M | 1 |
| Leschinger, N | 1 |
| Göldner, H | 1 |
| Knauf, W | 1 |
| Hopfenmüller, W | 1 |
| Thiel, E | 1 |
| Blau, O | 1 |
| Chang, C | 1 |
| Storer, BE | 1 |
| Scott, BL | 1 |
| Bryant, EM | 1 |
| Shulman, HM | 1 |
| Flowers, ME | 1 |
| Sandmaier, BM | 1 |
| Witherspoon, RP | 1 |
| Nash, RA | 1 |
| Bedalov, A | 1 |
| Hansen, JA | 1 |
| Clurman, BE | 1 |
| Storb, R | 1 |
| Deeg, HJ | 1 |
| Lu, C | 1 |
| Braine, HG | 1 |
| Kaizer, H | 1 |
| Saral, R | 1 |
| Tutschka, PJ | 1 |
| Santos, GW | 1 |
| Przepiorka, D | 2 |
| Ippoliti, C | 2 |
| Giralt, S | 1 |
| van Beisen, K | 1 |
| Mehra, R | 1 |
| Deisseroth, AB | 1 |
| Andersson, B | 1 |
| Luna, M | 2 |
| Cork, A | 1 |
| Lee, M | 1 |
| Dimopoulos, M | 1 |
| Smith, T | 1 |
| Diener, K | 1 |
| Champlin, RE | 1 |
| Mross, K | 1 |
| Bewermeier, P | 1 |
| Krüger, W | 1 |
| Stockschläder, M | 1 |
| Zander, A | 1 |
| Hossfeld, DK | 1 |
| Morris, JD | 1 |
| Harris, RE | 1 |
| Hashmi, R | 1 |
| Sambrano, JE | 1 |
| Gruppo, RA | 1 |
| Becker, AT | 1 |
| Morris, CL | 1 |
| Cohen, A | 1 |
| Rovelli, A | 1 |
| Bakker, B | 1 |
| Uderzo, C | 1 |
| van Lint, MT | 1 |
| Gaiero, A | 1 |
| Leiper, AD | 1 |
| Dopfer, R | 1 |
| Cahn, JY | 1 |
| Merlo, F | 1 |
| Kolb, HJ | 1 |
| Anger, G | 1 |
| Senf, L | 1 |
| Schmidt, U | 2 |
| Mattheus, A | 1 |
| Hussain, S | 1 |
| Mansi, J | 1 |
| da Costa, F | 1 |
| Viner, C | 1 |
| Judson, I | 1 |
| Gore, M | 1 |
| Cunningham, D | 1 |
| Wiktor-Jedrzejczak, W | 1 |
| Szczylik, C | 1 |
| Matej, H | 1 |
| Pojda, Z | 1 |
| Ratajczak, MZ | 1 |
| Myc, A | 1 |
| Siekierzyński, M | 1 |
| Kansy, J | 1 |
| Kłos, M | 1 |
| Rybicki, Z | 1 |
| Beelen, DW | 1 |
| Schilcher, RB | 1 |
| Ehrlich, R | 1 |
| Quabeck, K | 1 |
| Szy, D | 1 |
| Grosse-Wilde, H | 1 |
| Becher, R | 1 |
| Schaefer, UW | 1 |
| Hartmann, O | 1 |
| Benhamou, E | 1 |
| Beaujean, F | 1 |
| Pico, JL | 1 |
| Kalifa, C | 1 |
| Patte, C | 1 |
| Flamant, F | 1 |
| Lemerle, J | 1 |
| Bishop, JB | 1 |
| Wassom, JS | 1 |
| Saslaw, S | 1 |
| Carlisle, HN | 1 |
| Marcolongo, R | 1 |
| Di Paolo, N | 1 |
| Bianco, G | 1 |
| Bravi, A | 1 |
| Svetlichnyĭ, IS | 1 |
| Kovalenko, VL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| Trial Of Double Umbilical Cord Blood Transplantation[NCT00763490] | Phase 2 | 20 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING Study[NCT04936282] | Phase 4 | 80 participants (Anticipated) | Interventional | 2022-07-05 | Recruiting | ||
| Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome[NCT03858530] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-05-01 | Active, not recruiting | ||
| Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome[NCT03865589] | 250 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | |||
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients[NCT03963999] | Phase 4 | 0 participants (Actual) | Interventional | 2020-04-01 | Withdrawn (stopped due to We did not receive grant funding. We will reapply in June of 2020) | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies[NCT00923520] | Phase 1 | 60 participants (Actual) | Interventional | 2009-03-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
One-year survival rate after transplant (NCT00763490)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Double Cord Blood Tranplant | 40 |
Event Free Survival (EFS) was determined. Patients were followed up to 5 years (median time of 2.35 years). (NCT00763490)
Timeframe: 5 Years
| Intervention | percentage of patients (Number) |
|---|---|
| Double Cord Blood Tranplant | 35 |
The failure to achieve a neutrophil count > 500/uL or a platelet count >30.0 x 10e9 /L within 35 days of the stem cell infusion will be defined as primary engraftment failure. (NCT00763490)
Timeframe: Day 35
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Cumulative incidence of platlet engraftment | Cumulative incidence of neutrophil engraftment | |
| Double Cord Blood Tranplant | 73 | 89 |
"The percentage of patients with acute GVHD (Grade II-IV) was determined at 100 days. Patients were followed up to 5 years and the percentage of patients that developed chronic GVHD at the end of the study was tabulated.~Acute GVHD is staged and graded (grade 0-IV, where grade 0 is no involvement and involvement increases by grade) by the number and extent of organ involvement. Patients can have involvement of three organs: skin (rash/dermatitis), liver (hepatitis/jaundice), and gastrointestinal tract (abdominal pain/diarrhea)." (NCT00763490)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Acute GVHD (Grades II-IV) | Chronic GVHD | |
| Double Cord Blood Tranplant | 40 | 35 |
2 reviews available for busulfan and Blood Diseases
| Article | Year |
|---|---|
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Admi | 2014 |
Disorders of hemostasis and thrombosis in the aged.
Topics: Adolescent; Adult; Aged; Aortic Aneurysm; Blood Coagulation Disorders; Blood Coagulation Factors; Bl | 1976 |
8 trials available for busulfan and Blood Diseases
| Article | Year |
|---|---|
Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase.
Topics: Adult; Aged; Allografts; Autografts; Busulfan; Disease-Free Survival; Female; Hematologic Diseases; | 2017 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blo | 2014 |
Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bu | 2002 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2003 |
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Su | 2006 |
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; | 2008 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1994 |
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Hematologic Diseases; Humans | 1994 |
30 other studies available for busulfan and Blood Diseases
| Article | Year |
|---|---|
Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Area Under Curve; Busulfan; Child; Ch | 2020 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Dise | 2021 |
Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.
Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Follow-Up Studies; | 2014 |
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation].
Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Ant | 2014 |
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematolo | 2015 |
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databa | 2015 |
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.
Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; F | 2015 |
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution].
Topics: Adult; Aged; Allografts; Busulfan; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoieti | 2015 |
Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; CD3 Complex; Child; Down-Regulation; Fem | 2012 |
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Drug Administration Schedule; Female; Graft | 2013 |
Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera | 2013 |
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C | 2002 |
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Busulfan; Cyclophosphamide; Dose-Response R | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug In | 2006 |
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematol | 2007 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Pre | 2007 |
Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1984 |
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chromatography, | 1994 |
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; C | 1997 |
Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Body Height; Bone Marrow Transplantation; Busulfan | 1999 |
[Determination of serum vitamin B12 in hematologic diseases].
Topics: Acute Disease; Anemia, Pernicious; Busulfan; Hematologic Diseases; Humans; Leukemia; Leukemia, Myelo | 1979 |
High-dose busulfan in patients with myeloma.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Creatinine; Female; Hematol | 1992 |
Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1991 |
High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology study.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Dogs; Drug Evaluation, Precli | 1991 |
High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1986 |
Toxicological review of busulfan (Myleran).
Topics: Animals; Busulfan; Carcinogens; Cell Survival; Female; Hematologic Diseases; Humans; Immunity; Male; | 1986 |
Nonhuman primates in evaluation of hematotoxicity.
Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug-Related Side Effects and Adver | 1969 |
[Clinical usefulness of eticholanolone in the evaluation of bone marrow reserves in patients treated with myelosuppressive drugs and with radiotherapy].
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bone Marrow Diseases; Bone Marrow Examination | 1969 |
[On the problem of complications in Myelosan therapy].
Topics: Adult; Bone Marrow Diseases; Busulfan; Chemical and Drug Induced Liver Injury; Hematologic Diseases; | 1966 |